OCA
IMVT icon

Octagon Capital Advisors’s Immunovant IMVT Stock Holding History

Octagon Capital Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-273,289
Closed -$8.83M – 53
2024
Q1 		$8.83M Hold
273,289
– – 1.06% 27
2023
Q4 		$11.5M Buy
+273,289
New +$10.1M 1.84% 14
2022
Q4 		– Sell
-579,061
Closed -$3.23M – 41
2022
Q3 		$3.23M Hold
579,061
– – 0.56% 26
2022
Q2 		$2.26M Sell
579,061
-895,939
-61% -$3.87M 0.6% 16
2022
Q1 		$8.13M Buy
1,475,000
+902,138
+157% +$5.62M 1.76% 16
2021
Q4 		$4.88M Buy
+572,862
New +$4.73M 0.95% 20

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Octagon Capital Advisors's IMVT Position: Q2 2024 in Review

Octagon Capital Advisors sold out of Immunovant (IMVT) in Q2 2024, closing a stake of 273,289 shares — an estimated $8.83M sold.

Octagon Capital Advisors first reported a position in IMVT in Q4 2021 and held it in 6 quarters. The position peaked at $11.5M in Q4 2023. 197 funds tracked by Wall St. Rank hold IMVT as of Q2 2024.

  • Octagon Capital Advisors reported no remaining Immunovant position as of Q2 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 273,289 Immunovant shares in Q2 2024, an estimated $8.83M.
  • Octagon Capital Advisors first reported a position in Immunovant in Q4 2021 and held it in 6 quarters.
  • Octagon Capital Advisors's Immunovant position peaked at $11.5M in Q4 2023.
  • 197 funds tracked by Wall St. Rank held Immunovant as of Q2 2024.

Based on Octagon Capital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.